Cargando…
Adnectin–drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors
Tumor-specific delivery of cytotoxic agents remains a challenge in cancer therapy. Antibody–drug conjugates (ADC) deliver their payloads to tumor cells that overexpress specific tumor-associated antigens—but the multi-day half-life of ADC leads to high exposure even of normal, antigen-free, tissues...
Autores principales: | Lipovšek, Daša, Carvajal, Irvith, Allentoff, Alban J, Barros, Anthony, Brailsford, John, Cong, Qiang, Cotter, Pete, Gangwar, Sanjeev, Hollander, Cris, Lafont, Virginie, Lau, Wai Leung, Li, Wenying, Moreta, Miguel, O’Neil, Steven, Pinckney, Jason, Smith, Michael J, Su, Julie, Terragni, Christina, Wallace, Michael A, Wang, Lifei, Wright, Martin, Marsh, H Nicholas, Bryson, James W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158766/ https://www.ncbi.nlm.nih.gov/pubmed/30247737 http://dx.doi.org/10.1093/protein/gzy013 |
Ejemplares similares
-
Adnectins: engineered target-binding protein therapeutics
por: Lipovšek, D.
Publicado: (2011) -
Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology
por: Aghaabdollahian, Safieh, et al.
Publicado: (2019) -
Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008) -
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
por: Dineen, Sean P, et al.
Publicado: (2008) -
Huygens: science, payload and mission
por: Wilson, A
Publicado: (1997)